

# Karel Pacak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4091175/publications.pdf>

Version: 2024-02-01

498  
papers

36,219  
citations

2797

94  
h-index

4770

169  
g-index

509  
all docs

509  
docs citations

509  
times ranked

19871  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1915-1942.	1.8	2,031
2	Phaeochromocytoma. <i>Lancet</i> , The, 2005, 366, 665-675.	6.3	1,462
3	Biochemical Diagnosis of Pheochromocytoma. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 1427-34.	3.8	994
4	Irisin and FGF21 Are Cold-Induced Endocrine Activators of Brown Fat Function in Humans. <i>Cell Metabolism</i> , 2014, 19, 302-309.	7.2	643
5	Cushing's Syndrome Due to Ectopic Corticotropin Secretion: Twenty Years' Experience at the National Institutes of Health. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4955-4962.	1.8	588
6	Pheochromocytoma: recommendations for clinical practice from the First International Symposium. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 92-102.	2.9	581
7	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , 2017, 31, 181-193.	7.7	532
8	Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. <i>Annals of Internal Medicine</i> , 2001, 134, 315.	2.0	512
9	Preoperative Management of the Pheochromocytoma Patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4069-4079.	1.8	497
10	The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. <i>Pancreas</i> , 2010, 39, 775-783.	0.5	493
11	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. <i>Lancet Oncology</i> , The, 2009, 10, 764-771.	5.1	477
12	Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2656-2666.	1.8	447
13	Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. <i>European Journal of Human Genetics</i> , 2008, 16, 79-88.	1.4	446
14	Mapping of human brown adipose tissue in lean and obese young men. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8649-8654.	3.3	370
15	Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4757-4767.	1.8	361
16	Stress-Induced Norepinephrine Release in the Hypothalamic Paraventricular Nucleus and Pituitary-Adrenocortical and Sympathoadrenal Activity: In Vivo Microdialysis Studies. <i>Frontiers in Neuroendocrinology</i> , 1995, 16, 89-150.	2.5	348
17	Somatic <i>HIF2A</i> Gain-of-Function Mutations in Paraganglioma with Polycythemia. <i>New England Journal of Medicine</i> , 2012, 367, 922-930.	13.9	338
18	Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2262-2269.	0.8	316

#	ARTICLE	IF	CITATIONS
19	Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. <i>European Journal of Cancer</i> , 2012, 48, 1739-1749.	1.3	304
20	Malignant pheochromocytoma: current status and initiatives for future progress. <i>Endocrine-Related Cancer</i> , 2004, 11, 423-436.	1.6	299
21	High Frequency ofSDHBGermline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4505-4509.	1.8	299
22	Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 479-491.	1.8	296
23	Molecular Subtypes of <i>KIT/PDGFR</i> Wild-Type Gastrointestinal Stromal Tumors. <i>JAMA Oncology</i> , 2016, 2, 922.	3.4	291
24	Succinate Dehydrogenase Mutation Underlies Global Epigenomic Divergence in Gastrointestinal Stromal Tumor. <i>Cancer Discovery</i> , 2013, 3, 648-657.	7.7	288
25	Prospective Study of <sup>68</sup> Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. <i>Journal of Clinical Oncology</i> , 2016, 34, 588-596.	0.8	287
26	Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. <i>Clinical Chemistry</i> , 2011, 57, 411-420.	1.5	282
27	<i>MAX</i> Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2012, 18, 2828-2837.	3.2	277
28	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1999-2008.	1.8	262
29	Clinical Presentations, Biochemical Phenotypes, and Genotype-Phenotype Correlations in Patients with Succinate Dehydrogenase Subunit B-Associated Pheochromocytomas and Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 779-786.	1.8	262
30	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. <i>Endocrine Reviews</i> , 2017, 38, 489-515.	8.9	241
31	Staging and Functional Characterization of Pheochromocytoma and Paraganglioma by <sup>18</sup> F-Fluorodeoxyglucose ( <sup>18</sup> F-FDG) Positron Emission Tomography. <i>Journal of the National Cancer Institute</i> , 2012, 104, 700-708.	3.0	240
32	Superiority of 6-[ <sup>18</sup> F]-Fluorodopamine Positron Emission TomographyVersus [ <sup>131</sup> I]-Metaiodobenzylguanidine Scintigraphy in the Localization of Metastatic Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4083-4087.	1.8	237
33	Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine. <i>Cancer</i> , 2008, 113, 2020-2028.	2.0	234
34	EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1977-1995.	3.3	223
35	Superiority of [ <sup>68</sup> Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of <i>SDHB</i> -Associated Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2015, 21, 3888-3895.	3.2	223
36	The optimal imaging of adrenal tumours: a comparison of different methods. <i>Endocrine-Related Cancer</i> , 2007, 14, 587-599.	1.6	218

#	ARTICLE	IF	CITATIONS
37	6-[ <sup>18</sup> F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma. <i>Hypertension</i> , 2001, 38, 6-8.	1.3	215
38	Biochemical and Clinical Manifestations of Dopamine-Producing Paragangliomas: Utility of Plasma Methoxytyramine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2068-2075.	1.8	213
39	Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer. <i>Journal of Urology</i> , 2012, 188, 2063-2071.	0.2	211
40	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2112-2137.	3.3	208
41	Mitochondrial Complex II: At the Crossroads. <i>Trends in Biochemical Sciences</i> , 2017, 42, 312-325.	3.7	192
42	Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells. <i>Cell Metabolism</i> , 2019, 29, 399-416.e10.	7.2	190
43	Genetics, diagnosis, management and future directions of research of pheochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2020, 38, 1443-1456.	0.3	190
44	Monoamine Oxidase A-mediated Enhanced Catabolism of Norepinephrine Contributes to Adverse Remodeling and Pump Failure in Hearts With Pressure Overload. <i>Circulation Research</i> , 2010, 106, 193-202.	2.0	187
45	Current Treatment of Malignant Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1217-1225.	1.8	180
46	Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free Metanephrines. <i>Clinical Chemistry</i> , 2005, 51, 735-744.	1.5	177
47	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). <i>Modern Pathology</i> , 2015, 28, 807-821.	2.9	176
48	The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5367-5384.	1.8	174
49	Metastatic Pheochromocytoma/Paraganglioma Related to Primary Tumor Development in Childhood or Adolescence: Significant Link to SDHB Mutations. <i>Journal of Clinical Oncology</i> , 2011, 29, 4137-4142.	0.8	170
50	Catecholamine metabolomic and secretory phenotypes in pheochromocytoma. <i>Endocrine-Related Cancer</i> , 2010, 18, 97-111.	1.6	169
51	Pheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment. <i>Current Problems in Cancer</i> , 2014, 38, 7-41.	1.0	163
52	Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2001, 2, 297-311.	2.6	156
53	A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. <i>Journal of Molecular Medicine</i> , 2013, 91, 507-512.	1.7	155
54	Hypertension in Pheochromocytoma: Characteristics and Treatment. <i>Endocrinology and Metabolism Clinics of North America</i> , 2011, 40, 295-311.	1.2	153



#	ARTICLE	IF	CITATIONS
73	Adverse Drug Reactions in Patients with Pheochromocytoma. <i>Drug Safety</i> , 2007, 30, 1031-1062.	1.4	122
74	Pituitary Adenoma With Paraganglioma/Pheochromocytoma (3PAs) and Succinate Dehydrogenase Defects in Humans and Mice. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E710-E719.	1.8	121
75	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1122-1132.	1.8	120
76	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. <i>Cancers</i> , 2019, 11, 1505.	1.7	120
77	Heterogeneous neurochemical responses to different stressors: a test of Selye's doctrine of nonspecificity. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1998, 275, R1247-R1255.	0.9	119
78	Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1949-1956.	2.8	119
79	Central Nervous System Imprinting of the G Protein Gs $\alpha$ and Its Role in Metabolic Regulation. <i>Cell Metabolism</i> , 2009, 9, 548-555.	7.2	118
80	Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. <i>Journal of Molecular Medicine</i> , 2015, 93, 93-104.	1.7	118
81	Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2009, 16, 391-400.	1.6	117
82	Biochemical Diagnosis and Localization of Pheochromocytoma: Can We Reach a Consensus?. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 332-347.	1.8	115
83	New imaging approaches to pheochromocytomas and paragangliomas. <i>Clinical Endocrinology</i> , 2010, 72, 137-145.	1.2	112
84	Biochemically Silent Abdominal Paragangliomas in Patients with Mutations in the Succinate Dehydrogenase Subunit B Gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4826-4832.	1.8	111
85	Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3903-3911.	1.8	111
86	Noradrenergic activation in the paraventricular nucleus during acute and chronic immobilization stress in rats: an in vivo microdialysis study. <i>Brain Research</i> , 1992, 589, 91-96.	1.1	110
87	Is Supine Rest Necessary before Blood Sampling for Plasma Metanephrines?. <i>Clinical Chemistry</i> , 2007, 53, 352-354.	1.5	110
88	Characteristics And Outcomes Of Metastatic Sdhb And Sporadic Pheochromocytoma/Paraganglioma: An National Institutes Of Health Study. <i>Endocrine Practice</i> , 2016, 22, 302-314.	1.1	110
89	False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. <i>Endocrine-Related Cancer</i> , 2012, 19, 83-93.	1.6	106
90	Plasma Metadrenalines: Do they Provide Useful Information about Sympatho-Adrenal Function and Catecholamine Metabolism?. <i>Clinical Science</i> , 1995, 88, 533-542.	1.8	105

#	ARTICLE	IF	CITATIONS
91	Utility of Plasma Free Metanephrines for Detecting Childhood Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1955-1960.	1.8	104
92	Update on pediatric pheochromocytoma. <i>Pediatric Nephrology</i> , 2009, 24, 943-950.	0.9	102
93	The Effects of Carbidopa on Uptake of 6-18F-Fluoro-L-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1599-1606.	2.8	101
94	Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of pheochromocytoma. <i>Annals of Clinical Biochemistry</i> , 2013, 50, 62-69.	0.8	98
95	Prospective comparison of 68Ga-DOTATATE and 18F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1248-1257.	3.3	96
96	Drugs and Pheochromocytoma – Don't Be Fooled by Every Elevated Metanephrine. <i>New England Journal of Medicine</i> , 2011, 364, 2268-2270.	13.9	95
97	New Roles of Carboxypeptidase E in Endocrine and Neural Function and Cancer. <i>Endocrine Reviews</i> , 2012, 33, 216-253.	8.9	95
98	Effects of immobilization on in vivo release of norepinephrine in the bed nucleus of the stria terminalis in conscious rats. <i>Brain Research</i> , 1995, 688, 242-246.	1.1	92
99	Downregulation of metastasis suppressor genes in malignant pheochromocytoma. <i>International Journal of Cancer</i> , 2005, 114, 139-143.	2.3	92
100	Brown Fat Imaging with 18F-6-Fluorodopamine PET/CT, 18F-FDG PET/CT, and 123I-MIBG SPECT: A Study of Patients Being Evaluated for Pheochromocytoma. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1077-1083.	2.8	92
101	Metastatic Paraganglioma. <i>Seminars in Oncology</i> , 2010, 37, 627-637.	0.8	91
102	Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 375-384.	1.8	90
103	Cardiac sympathetic denervation preceding motor signs in Parkinson disease. <i>Clinical Autonomic Research</i> , 2007, 17, 118-121.	1.4	88
104	Pheochromocytoma as an endocrine emergency. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2003, 4, 121-128.	2.6	87
105	Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. <i>Blood</i> , 2013, 121, 2563-2566.	0.6	87
106	Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis. <i>Endocrine-Related Cancer</i> , 2019, 26, 539-550.	1.6	87
107	Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature. <i>European Journal of Endocrinology</i> , 2008, 158, 423-429.	1.9	86
108	Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. <i>Nuclear Medicine Communications</i> , 2006, 27, 31-36.	0.5	85

#	ARTICLE	IF	CITATIONS
109	Partial Adrenalectomy: Underused First Line Therapy for Small Adrenal Tumors. <i>Journal of Urology</i> , 2010, 184, 18-25.	0.2	85
110	15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2015, 22, T135-T145.	1.6	84
111	Radiofrequency Ablation: a Novel Approach for Treatment of Metastatic Pheochromocytoma. <i>Journal of the National Cancer Institute</i> , 2001, 93, 648-649.	3.0	83
112	Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging. <i>Frontiers in Endocrinology</i> , 2018, 9, 515.	1.5	82
113	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1999-2008.	1.8	81
114	Minimal changes in environmental temperature result in a significant increase in energy expenditure and changes in the hormonal homeostasis in healthy adults. <i>European Journal of Endocrinology</i> , 2010, 163, 863-872.	1.9	80
115	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. <i>Nature Reviews Endocrinology</i> , 2021, 17, 435-444.	4.3	80
116	Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. <i>Endocrine</i> , 2017, 56, 495-503.	1.1	79
117	Impaired Basal and Restraint-Induced Epinephrine Secretion in Corticotropin-Releasing Hormone-Deficient Mice. <i>Endocrinology</i> , 2000, 141, 1142-1150.	1.4	78
118	The role of 6-[ <sup>18</sup> F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. <i>European Journal of Endocrinology</i> , 2007, 156, 483-487.	1.9	78
119	SDH-related pheochromocytoma and paraganglioma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2010, 24, 415-424.	2.2	78
120	Subclinical pheochromocytoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012, 26, 507-515.	2.2	76
121	Pheochromocytoma in von Hippel-Lindau Disease: Distinct Histopathologic Phenotype Compared to Pheochromocytoma in Multiple Endocrine Neoplasia Type 2. <i>Endocrine Pathology</i> , 2002, 13, 17-28.	5.2	74
122	Use of <sup>18</sup> F-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic pheochromocytoma (PHEO). <i>Clinical Endocrinology</i> , 2009, 71, 11-17.	1.2	74
123	Plasma metanephrines in renal failure. <i>Kidney International</i> , 2005, 67, 668-677.	2.6	73
124	Opposing effects of HIF1 $\alpha$ and HIF2 $\alpha$ on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X. <i>International Journal of Cancer</i> , 2014, 135, 2054-2064.	2.3	72
125	Results of <sup>68</sup> Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. <i>Journal of the American College of Surgeons</i> , 2015, 221, 509-517.	0.2	72
126	Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. <i>Endocrine-Related Cancer</i> , 2019, 26, R627-R652.	1.6	72



#	ARTICLE	IF	CITATIONS
127	Genomic Landscape of Pheochromocytoma and Paraganglioma. <i>Trends in Cancer</i> , 2018, 4, 6-9.	3.8	71
128	CRH Deficiency Impairs but Does Not Block Pituitary-Adrenal Responses to Diverse Stressors. <i>Neuroendocrinology</i> , 2000, 71, 79-87.	1.2	68
129	New Advances in the Biochemical Diagnosis of Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2002, 970, 29-40.	1.8	68
130	Correlation Between In Vivo <sup>18</sup> F-FDG PET and Immunohistochemical Markers of Glucose Uptake and Metabolism in Pheochromocytoma and Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1253-1259.	2.8	67
131	Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 295, E1223-E1233.	1.8	66
132	Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma in Patients With von Hippel-Lindau Syndrome After at Least 5 Years of Followup. <i>Journal of Urology</i> , 2010, 184, 1855-1859.	0.2	66
133	Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 966-971.	3.3	66
134	New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 66-72.	3.1	65
135	Emergencies Caused by Pheochromocytoma, Neuroblastoma, or Ganglioneuroma. <i>Endocrinology and Metabolism Clinics of North America</i> , 2006, 35, 699-724.	1.2	65
136	Effects of Single or Repeated Immobilization on Release of Norepinephrine and Its Metabolites in the Central Nucleus of the Amygdala in Conscious Rats. <i>Neuroendocrinology</i> , 1993, 57, 626-633.	1.2	64
137	Interrelations between Sympathoadrenal System and Hypothalamo-Pituitary-Adrenocortical/Thyroid Systems in Rats Exposed to Cold Stress. <i>Journal of Neuroendocrinology</i> , 1996, 8, 533-541.	1.2	64
138	INCREASED PLASMA NOREPINEPHRINE CONCENTRATION IN CATS WITH INTERSTITIAL CYSTITIS. <i>Journal of Urology</i> , 2001, 165, 2051-2054.	0.2	64
139	Localization of Medullary Thyroid Carcinoma Metastasis in a Multiple Endocrine Neoplasia Type 2A Patient by 6-[ <sup>18</sup> F]-Fluorodopamine Positron Emission Tomography. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 637-641.	1.8	64
140	A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. <i>Nuclear Medicine and Biology</i> , 2008, 35, S27-S34.	0.3	64
141	Superiority of <sup>68</sup> Ga-DOTATATE over <sup>18</sup> F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 787-797.	3.3	64
142	Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. <i>Oncotarget</i> , 2017, 8, 56110-56125.	0.8	64
143	Succinate-to-Fumarate Ratio as a New Metabolic Marker to Detect the Presence of SDHB/D-related Paraganglioma: Initial Experimental and Ex Vivo Findings. <i>Endocrinology</i> , 2014, 155, 27-32.	1.4	63
144	SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1421-1435.	1.2	63

#	ARTICLE	IF	CITATIONS
145	PheoSeq. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 575-588.	1.2	63
146	Stress-Induced Norepinephrine Release in the Paraventricular Nucleus of Rats with Brainstem Hemisections: A Microdialysis Study. <i>Neuroendocrinology</i> , 1993, 58, 196-201.	1.2	62
147	Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 239-250.	1.7	62
148	Novel insights into the polycythemiaâ€“paragangliomaâ€“somatostatinoma syndrome. <i>Endocrine-Related Cancer</i> , 2016, 23, 899-908.	1.6	62
149	Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors. <i>Gastroenterology</i> , 2018, 154, 998-1008.e1.	0.6	62
150	Current Role of Metaiodobenzylguanidine in the Diagnosis of Pheochromocytoma and Medullary Thyroid Cancer. <i>Seminars in Nuclear Medicine</i> , 2011, 41, 364-368.	2.5	61
151	An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. <i>Journal of Clinical Investigation</i> , 2011, 121, 880-892.	3.9	61
152	Diagnostic Localization of Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2002, 970, 170-176.	1.8	60
153	Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. <i>Endocrine-Related Cancer</i> , 2008, 15, 311-323.	1.6	60
154	Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4498-4504.	1.8	60
155	Metabolome Profiling by HRMAS NMR Spectroscopy of Pheochromocytomas and Paragangliomas Detects SDH Deficiency: Clinical and Pathophysiological Implications. <i>Neoplasia</i> , 2015, 17, 55-65.	2.3	60
156	SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. <i>Surgery</i> , 2017, 161, 230-239.	1.0	60
157	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. <i>Genetics in Medicine</i> , 2019, 21, 705-717.	1.1	60
158	Gene Expression Profiling of Benign and Malignant Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 541-556.	1.8	59
159	Pheochromocytoma: The First Metabolic Endocrine Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5001-5011.	3.2	59
160	Pheochromocytoma and Paraganglioma. <i>Progress in Brain Research</i> , 2010, 182, 343-373.	0.9	58
161	Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. <i>Journal of Clinical Oncology</i> , 2017, 35, 523-528.	0.8	58
162	Precision Medicine: An Update on Genotype/Biochemical Phenotype Relationships in Pheochromocytoma/Paraganglioma Patients. <i>Endocrine Practice</i> , 2017, 23, 690-704.	1.1	58

#	ARTICLE	IF	CITATIONS
163	Different expression of catecholamine transporters in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. <i>European Journal of Endocrinology</i> , 2005, 153, 551-563.	1.9	57
164	Carney triad can be (rarely) associated with germline succinate dehydrogenase defects. <i>European Journal of Human Genetics</i> , 2016, 24, 569-573.	1.4	57
165	Targeting NAD <sup>+</sup> /PARP DNA Repair Pathway as a Novel Therapeutic Approach to <i>SDHB</i> -Mutated Cluster I Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2018, 24, 3423-3432.	3.2	57
166	Genetic Testing for Pheochromocytoma. <i>Current Hypertension Reports</i> , 2010, 12, 456-464.	1.5	56
167	The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with <i>SDHB</i> -related pheochromocytoma and paraganglioma: a retrospective cohort study. <i>BMC Cancer</i> , 2014, 14, 523.	1.1	55
168	New Insights into the Genetics of Familial Chromaffin Cell Tumors. <i>Annals of the New York Academy of Sciences</i> , 2002, 970, 11-28.	1.8	54
169	Biochemical Diagnosis of Pheochromocytoma. , 2003, 31, 76-106.		54
170	First Report of Bilateral Pheochromocytoma in the Clinical Spectrum of <i>HIF2A</i> -Related Polycythemia-Paraganglioma Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E908-E913.	1.8	54
171	Pheochromocytoma and Paraganglioma. <i>Endocrine Practice</i> , 2015, 21, 406-412.	1.1	54
172	Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2013, 19, 3787-3795.	3.2	53
173	Protocol for the Examination of Specimens From Patients With Pheochromocytomas and Extra-Adrenal Paragangliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 182-188.	1.2	52
174	A "Pheo" Lurks: Novel Approaches for Locating Occult Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3641-3646.	1.8	51
175	Radiofrequency Ablation of Metastatic Pheochromocytoma. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 1483-1490.	0.2	51
176	Genetics of pheochromocytoma and paraganglioma syndromes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013, 20, 186-191.	1.2	51
177	External Beam Radiation Therapy in Treatment of Malignant Pheochromocytoma and Paraganglioma. <i>Frontiers in Oncology</i> , 2014, 4, 166.	1.3	51
178	Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: How to Manage a Rare Complication in a Rare Disease?. <i>Hormone and Metabolic Research</i> , 2019, 51, 458-469.	0.7	51
179	Laparoscopic Management of Extra-Adrenal Pheochromocytoma. <i>Journal of Urology</i> , 2004, 171, 72-76.	0.2	50
180	Current Trends in Functional Imaging of Pheochromocytomas and Paragangliomas. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 374-382.	1.8	50

#	ARTICLE	IF	CITATIONS
181	The Presence of SDHB Mutations Should Modify Surgical Indications for Carotid Body Paragangliomas. <i>Annals of Surgery</i> , 2014, 260, 158-162.	2.1	50
182	Imaging of Pheochromocytoma and Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1033-1042.	2.8	50
183	Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by <sup>18</sup> F- $\beta$ -CIT PET: focus on missed lesions. <i>Clinical Endocrinology</i> , 2013, 79, 170-177.	1.2	49
184	Catecholamine physiology and its implications in patients with COVID-19. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 978-986.	5.5	49
185	Effects of Hypo- and Hyperthyroidism on Noradrenergic Activity and Glycerol Concentrations in Human Subcutaneous Abdominal Adipose Tissue Assessed with Microdialysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5605-5608.	1.8	48
186	Brief Communication: Radiographic Contrast Infusion and Catecholamine Release in Patients With Pheochromocytoma. <i>Annals of Internal Medicine</i> , 2009, 150, 27.	2.0	48
187	Familial pheochromocytomas and paragangliomas. <i>Molecular and Cellular Endocrinology</i> , 2014, 386, 92-100.	1.6	47
188	Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. <i>Surgery</i> , 2017, 161, 220-227.	1.0	47
189	Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma. <i>Oncogene</i> , 2001, 20, 7809-7811.	2.6	46
190	Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. <i>FASEB Journal</i> , 2012, 26, 4506-4516.	0.2	46
191	Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. <i>Journal of Hypertension</i> , 2005, 23, 2033-2039.	0.3	45
192	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. <i>Genetics in Medicine</i> , 2018, 20, 1652-1662.	1.1	45
193	Mutations associated with succinate dehydrogenase $\beta$ -related malignant paragangliomas. <i>Clinical Endocrinology</i> , 2008, 68, 561-566.	1.2	44
194	Combined blockade of signalling pathways shows marked anti-tumour potential in pheochromocytoma cell lines. <i>Journal of Molecular Endocrinology</i> , 2012, 49, 79-96.	1.1	44
195	Response after Surgical Resection of Metastatic Pheochromocytoma and Paraganglioma: Can Postoperative Biochemical Remission Be Predicted?. <i>Journal of the American College of Surgeons</i> , 2013, 217, 489-496.	0.2	44
196	Alternative assembly of respiratory complex II connects energy stress to metabolic checkpoints. <i>Nature Communications</i> , 2018, 9, 2221.	5.8	44
197	Adipocyte $\beta$ -arrestin-2 is essential for maintaining whole body glucose and energy homeostasis. <i>Nature Communications</i> , 2019, 10, 2936.	5.8	43
198	Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 85.	1.3	43

#	ARTICLE	IF	CITATIONS
199	Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. <i>Journal of Hypertension</i> , 2007, 25, 2286-2295.	0.3	42
200	Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. <i>Endocrine-Related Cancer</i> , 2009, 16, 291-299.	1.6	42
201	Metastatic pheochromocytoma: Does the size and age matter?. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1121-1128.	1.7	42
202	High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2021, 27, 2989-2995.	3.2	42
203	Chronic Hypercortisolemia Inhibits Dopamine Synthesis and Turnover in the Nucleus accumbens: An in vivo Microdialysis Study. <i>Neuroendocrinology</i> , 2002, 76, 148-157.	1.2	41
204	Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude Mice. <i>Endocrinology</i> , 2013, 154, 646-655.	1.4	41
205	Diagnosis and Localization of Pheochromocytoma. <i>Hypertension</i> , 2004, 43, 907-910.	1.3	40
206	Anatomical and Functional Imaging of Metastatic Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2004, 1018, 495-504.	1.8	40
207	Clinical utility of chromogranin A in SDH-related paragangliomas. <i>European Journal of Clinical Investigation</i> , 2014, 44, 365-371.	1.7	40
208	The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management. <i>Urology</i> , 2014, 83, 1225-1232.	0.5	40
209	Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 117-128.	0.6	40
210	The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. <i>Journal of the Autonomic Nervous System</i> , 1994, 50, 93-107.	1.9	39
211	The Adrenal Medulla and Extra-adrenal Paraganglia: Then and Now. <i>Endocrine Pathology</i> , 2014, 25, 49-58.	5.2	39
212	Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. <i>Frontiers in Oncology</i> , 2019, 9, 53.	1.3	39
213	A New Specific Succinate-Glutamate Metabolomic Hallmark in Sdhx-Related Paragangliomas. <i>PLoS ONE</i> , 2013, 8, e80539.	1.1	39
214	Elevated Inflammation Markers in Pheochromocytoma Compared to Other Forms of Hypertension. <i>NeuroImmunoModulation</i> , 2007, 14, 57-64.	0.9	38
215	Gs1± Deficiency in Adipose Tissue Leads to a Lean Phenotype with Divergent Effects on Cold Tolerance and Diet-Induced Thermogenesis. <i>Cell Metabolism</i> , 2010, 11, 320-330.	7.2	38
216	In vivo micro-CT imaging of liver lesions in small animal models. <i>Methods</i> , 2010, 50, 20-25.	1.9	38

#	ARTICLE	IF	CITATIONS
217	Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total <sup>68</sup> Ga-DOTATATE-Avid tumor volume measurements. <i>European Journal of Endocrinology</i> , 2017, 176, 575-582.	1.9	38
218	Glycine stimulates striatal dopamine release in conscious rats. <i>British Journal of Pharmacology</i> , 1993, 110, 50-53.	2.7	37
219	Increased uptake of [ <sup>123</sup> I]meta-iodobenzylguanidine, [ <sup>18</sup> F]fluorodopamine, and [ <sup>3</sup> H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. <i>Endocrine-Related Cancer</i> , 2011, 18, 143-157.	1.6	37
220	Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. <i>Cell and Tissue Research</i> , 2018, 372, 393-401.	1.5	37
221	Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. <i>Gland Surgery</i> , 2020, 9, 105-123.	0.5	37
222	Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. <i>Hormones</i> , 2009, 8, 111-116.	0.9	36
223	ZNF367 Inhibits Cancer Progression and Is Targeted by miR-195. <i>PLoS ONE</i> , 2014, 9, e101423.	1.1	36
224	Medullary Thyroid Carcinoma: An Update on Imaging. <i>Journal of Thyroid Research</i> , 2019, 2019, 1-17.	0.5	36
225	Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1996, 354, 287-94.	1.4	34
226	Noninvasive monitoring of a murine model of metastatic pheochromocytoma: A comparison of contrast-enhanced microCT and nonenhanced MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2009, 29, 685-691.	1.9	34
227	Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. <i>Hypertension Research</i> , 2010, 33, 454-459.	1.5	34
228	NF- $\kappa$ B inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model. <i>International Journal of Cancer</i> , 2012, 131, 2445-2455.	2.3	34
229	Role of Hypoxia and HIF1 $\alpha$ in Development of the Sympathoadrenal Cell Lineage and Chromaffin Cell Tumors with Distinct Catecholamine Phenotypic Features. <i>Advances in Pharmacology</i> , 2013, 68, 285-317.	1.2	34
230	Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. <i>Endocrine-Related Cancer</i> , 2015, 22, M1-M8.	1.6	34
231	New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 807-817.	3.1	34
232	Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors. <i>JAMA Surgery</i> , 2019, 154, 40.	2.2	34
233	Somatic VHL gene deletion and point mutation in MEN2A-associated pheochromocytoma. <i>Oncogene</i> , 2002, 21, 479-482.	2.6	33
234	Bilateral Adrenal Medullary Hyperplasia Associated With an <i>SDHB</i> Mutation. <i>Journal of Clinical Oncology</i> , 2011, 29, e200-e202.	0.8	33

#	ARTICLE	IF	CITATIONS
235	Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging. <i>Frontiers in Oncology</i> , 2011, 1, 58.	1.3	33
236	Genotype and Tumor Locus Determine Expression Profile of Pseudohypoxic Pheochromocytomas and Paragangliomas. <i>Neoplasia</i> , 2013, 15, 435-IN22.	2.3	33
237	Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies. <i>Cancers</i> , 2019, 11, 436.	1.7	33
238	HIF2 $\alpha$ supports pro-metastatic behavior in pheochromocytomas/paragangliomas. <i>Endocrine-Related Cancer</i> , 2020, 27, 625-640.	1.6	33
239	New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications. <i>Cancers</i> , 2022, 14, 594.	1.7	33
240	Cerebrospinal Fluid Catecholamine Levels as Predictors of Outcome in Subarachnoid Hemorrhage. <i>Cerebrovascular Diseases</i> , 2012, 33, 173-181.	0.8	32
241	Warburg Effect <sup>TM</sup> 's Manifestation in Aggressive Pheochromocytomas and Paragangliomas: Insights from a Mouse Cell Model Applied to Human Tumor Tissue. <i>PLoS ONE</i> , 2012, 7, e40949.	1.1	32
242	Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery. <i>Surgery</i> , 2018, 163, 191-196.	1.0	32
243	Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly Sensitizes PHEO in a MPC Cell and Mouse Model to Conventional Chemotherapy. <i>PLoS ONE</i> , 2011, 6, e14678.	1.1	32
244	Brainstem Hemisection Decreases Corticotropin-Releasing Hormone mRNA in the Paraventricular Nucleus but not in the Central Amygdaloid Nucleus. <i>Journal of Neuroendocrinology</i> , 1996, 8, 543-551.	1.2	31
245	Survivin: a novel neuroendocrine marker for pheochromocytoma. <i>European Journal of Endocrinology</i> , 2002, 146, 381-388.	1.9	31
246	Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2014, 21, R261-R277.	1.6	31
247	Documenting stress in caregivers of transplantation patients: initial evidence of HPA dysregulation. <i>Stress</i> , 2016, 19, 175-184.	0.8	31
248	Role of CRH in Glucopenia-Induced Adrenomedullary Activation in Rats. <i>Journal of Neuroendocrinology</i> , 1993, 5, 475-486.	1.2	30
249	MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice. <i>International Journal of Cancer</i> , 2006, 119, 2236-2241.	2.3	30
250	Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl. <i>Endocrine-Related Cancer</i> , 2010, 17, 581-588.	1.6	30
251	Murine Models and Cell Lines for the Investigation of Pheochromocytoma: Applications for Future Therapies?. <i>Endocrine Pathology</i> , 2012, 23, 43-54.	5.2	30
252	<sup>18</sup> F- $\beta$ -FDG PET/CT as a predictor of hereditary head and neck paragangliomas. <i>European Journal of Clinical Investigation</i> , 2014, 44, 325-332.	1.7	30

#	ARTICLE	IF	CITATIONS
253	Succinate Dehydrogenase Gene Mutations in Cardiac Paragangliomas. <i>American Journal of Cardiology</i> , 2015, 115, 1753-1759.	0.7	30
254	Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma. <i>Journal of the American College of Cardiology</i> , 2020, 76, 451-464.	1.2	30
255	Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1051-1063.	1.2	30
256	Somatic VHLgene alterations in MEN2-associated medullary thyroid carcinoma. <i>BMC Cancer</i> , 2006, 6, 131.	1.1	29
257	Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1236-1242.	2.8	29
258	Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway. <i>Oncotarget</i> , 2017, 8, 22313-22324.	0.8	29
259	Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. <i>Clinical Cancer Research</i> , 2020, 26, 3868-3880.	3.2	29
260	Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 278-282.	3.3	28
261	Stressor-Specific Activation of Catecholaminergic Systems: Implications for Stress-Related Hypothalamic-Pituitary-Adrenocortical Responses. <i>Advances in Pharmacology</i> , 1997, 42, 561-564.	1.2	27
262	Low Sensitivity of Glucagon Provocative Testing for Diagnosis of Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 238-245.	1.8	27
263	The Evolving Role of Succinate in Tumor Metabolism: An <sup>18</sup> F-FDG-Based Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1749-1755.	2.8	27
264	18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1574-1582.	1.8	27
265	Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy. <i>Cellular and Molecular Neurobiology</i> , 2018, 38, 1099-1106.	1.7	27
266	Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491876336.	0.6	27
267	Differential Expression of Erythropoietin and Its Receptor in von Hippel-Lindau-Associated and Multiple Endocrine Neoplasia Type 2-Associated Pheochromocytomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3747-3751.	1.8	26
268	Leptin concentrations in the abdominal subcutaneous adipose tissue of patients with anorexia nervosa assessed by in vivo microdialysis. <i>Regulatory Peptides</i> , 2005, 128, 63-68.	1.9	26
269	Determinants of Central Sympathetic Activation in Spontaneous Primary Subarachnoid Hemorrhage. <i>Neurocritical Care</i> , 2012, 16, 381-388.	1.2	26
270	Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia. <i>Human Genome Variation</i> , 2015, 2, 15053.	0.4	26



#	ARTICLE	IF	CITATIONS
271	Pheochromocytoma: Gasping for Air. <i>Hormones and Cancer</i> , 2015, 6, 191-205.	4.9	26
272	The microenvironment induces collective migration in SDHB-silenced mouse pheochromocytoma spheroids. <i>Endocrine-Related Cancer</i> , 2017, 24, 555-564.	1.6	26
273	Choice of biochemical test for diagnosis of pheochromocytoma: Validation of plasma metanephrines. <i>Current Hypertension Reports</i> , 2002, 4, 250-255.	1.5	25
274	Hypotension in a Woman with a Metastatic Dopamine-Secreting Carotid Body Tumor. <i>Endocrine Practice</i> , 2003, 9, 310-314.	1.1	25
275	Overexpression of Interleukin-13 Receptor- $\alpha 2$ in Neuroendocrine Malignant Pheochromocytoma: A Novel Target for Receptor Directed Anti-Cancer Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2952-2957.	1.8	25
276	Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation. <i>Endocrine Pathology</i> , 2017, 28, 302-307.	5.2	25
277	Postoperative Management in Patients with Pheochromocytoma and Paraganglioma. <i>Cancers</i> , 2019, 11, 936.	1.7	25
278	Phosphoprotein-based biomarkers as predictors for cancer therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18401-18411.	3.3	25
279	Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas. <i>Frontiers in Endocrinology</i> , 2021, 12, 589451.	1.5	25
280	Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. <i>Frontiers in Endocrinology</i> , 2021, 12, 625312.	1.5	25
281	INCREASED PLASMA NOREPINEPHRINE CONCENTRATION IN CATS WITH INTERSTITIAL CYSTITIS. <i>Journal of Urology</i> , 2001, 165, 2051-2054.	0.2	25
282	A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position. <i>European Journal of Endocrinology</i> , 2019, 181, 301-309.	1.9	25
283	Diagnostic Localization of Malignant Bladder Pheochromocytoma Using 6-[ <sup>18</sup> F]Fluorodopamine Positron Emission Tomography. <i>Journal of Urology</i> , 2003, 169, 274-275.	0.2	24
284	Transcriptional Regulation of Phenylethanolamine N-Methyltransferase in Pheochromocytomas from Patients with von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 241-252.	1.8	24
285	Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. <i>Clinical Endocrinology</i> , 2014, 81, 317-328.	1.2	24
286	Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 167.e13-167.e20.	0.8	24
287	The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance. <i>Endocrine-Related Cancer</i> , 2018, 25, 893-908.	1.6	24
288	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. <i>Endocrinology</i> , 2019, 160, 2600-2617.	1.4	24

#	ARTICLE	IF	CITATIONS
289	Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2 $\beta$ in Pheochromocytoma Cells. <i>Cancers</i> , 2019, 11, 594.	1.7	24
290	Anti-Cancer Potential of MAPK Pathway Inhibition in Paragangliomas—Effect of Different Statins on Mouse Pheochromocytoma Cells. <i>PLoS ONE</i> , 2014, 9, e97712.	1.1	24
291	Chronic blockade of nitric oxide synthesis elevates plasma levels of catecholamines and their metabolites at rest and during stress in rats. <i>Neurochemical Research</i> , 1997, 22, 995-1001.	1.6	23
292	Usefulness of Standardized Uptake Values for Distinguishing Adrenal Glands with Pheochromocytoma from Normal Adrenal Glands by Use of 6-18F-Fluorodopamine PET. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1940-1944.	2.8	23
293	Candidate Genes Associated With Malignant Pheochromocytomas by Genome-Wide Expression Profiling. <i>Annals of Surgery</i> , 2009, 250, 983-990.	2.1	23
294	Current and Future Trends in the Anatomical and Functional Imaging of Head and Neck Paragangliomas. <i>Seminars in Nuclear Medicine</i> , 2013, 43, 462-473.	2.5	23
295	Targeting Heat Shock Protein 90 for the Treatment of Malignant Pheochromocytoma. <i>PLoS ONE</i> , 2013, 8, e56083.	1.1	23
296	Ocular Manifestations of Hypoxia-Inducible Factor-2 $\beta$ Paraganglioma-Somatostatinoma-Polycythemia Syndrome. <i>Ophthalmology</i> , 2014, 121, 2291-2293.	2.5	23
297	Carney triad, SDH-deficient tumors, and Sdhb+/ $\Delta$ mice share abnormal mitochondria. <i>Endocrine-Related Cancer</i> , 2015, 22, 345-352.	1.6	23
298	Pendrin localizes to the adrenal medulla and modulates catecholamine release. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 309, E534-E545.	1.8	23
299	Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells. <i>Cell and Tissue Research</i> , 2018, 374, 473-485.	1.5	23
300	Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. <i>Cancers</i> , 2019, 11, 809.	1.7	23
301	Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in pheochromocytomas and paragangliomas. <i>Journal of Pathology</i> , 2020, 251, 378-387.	2.1	23
302	Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma. <i>Cancers</i> , 2020, 12, 280.	1.7	23
303	Expression of the noradrenaline transporter and phenylethanolamine N-methyltransferase in normal human adrenal gland and pheochromocytoma. <i>Cell and Tissue Research</i> , 2005, 322, 443-453.	1.5	22
304	Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2008, 1148, 462-468.	1.8	22
305	Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging. <i>Cancer Letters</i> , 2012, 316, 46-52.	3.2	22
306	A Transgenic Mouse Model of Pacak—Zhuang Syndrome with An Epas1 Gain-of-Function Mutation. <i>Cancers</i> , 2019, 11, 667.	1.7	22

#	ARTICLE	IF	CITATIONS
307	The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors. <i>Hormone and Metabolic Research</i> , 2019, 51, 419-436.	0.7	22
308	What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?. <i>Endocrine Pathology</i> , 2021, 32, 134-153.	5.2	22
309	Comprehensive review of evaluation and management of cardiac paragangliomas. <i>Heart</i> , 2020, 106, 1202-1210.	1.2	22
310	The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40. <i>Cancers</i> , 2019, 11, 654.	1.7	21
311	Germline <i>SUCLG2</i> Variants in Patients With Pheochromocytoma and Paraganglioma. <i>Journal of the National Cancer Institute</i> , 2022, 114, 130-138.	3.0	21
312	Drugs and pheochromocytoma—don't be fooled by every elevated metanephrine. <i>New England Journal of Medicine</i> , 2011, 364, 2268-70.	13.9	21
313	The Incidentally Discovered Adrenal Mass. <i>New England Journal of Medicine</i> , 2007, 356, 2005-2006.	13.9	20
314	The Use of Functional Imaging in a Patient with Head and Neck Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 481-482.	1.8	20
315	Urinary Bladder Paragangliomas. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1488-1492.	2.1	20
316	HIF2A gain-of-function mutations detected in duodenal gangliocytic paraganglioma. <i>Endocrine-Related Cancer</i> , 2016, 23, L13-L16.	1.6	20
317	<sup>18</sup> F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 812-821.	3.3	20
318	An assessment of biochemical tests for the diagnosis of pheochromocytoma. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 744-745.	2.9	19
319	Exercise-induced nausea and vomiting: another sign and symptom of pheochromocytoma and paraganglioma. <i>Endocrine</i> , 2010, 37, 403-407.	1.1	19
320	Integrated Whole-Body PET/MRI With <sup>18</sup> F-FDG, <sup>18</sup> F-FDOPA, and <sup>18</sup> F-FDA in Paragangliomas in Comparison With PET/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, 243-250.	0.7	19
321	Pathology of Human Pheochromocytoma and Paraganglioma Xenografts in NSG Mice. <i>Endocrine Pathology</i> , 2017, 28, 2-6.	5.2	19
322	A Reduction in Pten Tumor Suppressor Activity Promotes ErbB-2-Induced Mouse Prostate Adenocarcinoma Formation through the Activation of Signaling Cascades Downstream of PDK1. <i>American Journal of Pathology</i> , 2009, 174, 2051-2060.	1.9	18
323	Renaissance of <sup>18</sup> F-FDG Positron Emission Tomography in the Imaging of Pheochromocytoma/Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2337-2339.	1.8	18
324	Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. <i>Journal of Neuro-Oncology</i> , 2016, 126, 473-481.	1.4	18

#	ARTICLE	IF	CITATIONS
325	Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1176-1185.	1.8	18
326	Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma. <i>European Journal of Cancer</i> , 2022, 169, 32-41.	1.3	18
327	ErbB-2 Induces Bilateral Adrenal Pheochromocytoma Formation in Mice. <i>Cell Cycle</i> , 2007, 6, 1946-1950.	1.3	17
328	Malignant paraganglioma associated with succinate dehydrogenase subunit B in an 8-year-old child: the age of first screening?. <i>Pediatric Nephrology</i> , 2009, 24, 1239-1242.	0.9	17
329	Association between acute sympathetic response, early onset vasospasm, and delayed vasospasm following spontaneous subarachnoid hemorrhage. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 256-262.	0.8	17
330	Lack of utility of SDHB mutation testing in adrenergic metastatic pheochromocytoma. <i>European Journal of Endocrinology</i> , 2015, 172, 89-95.	1.9	17
331	New insights on the pathogenesis of paraganglioma and pheochromocytoma. <i>F1000Research</i> , 2018, 7, 1500.	0.8	17
332	Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma. <i>Endocrine</i> , 2008, 34, 96-100.	1.1	16
333	Hypoxia-Inducible Factor 2 $\alpha$ Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. <i>Neoplasia</i> , 2016, 18, 567-576.	2.3	16
334	HIF-2 $\alpha$ : Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions. <i>European Journal of Cancer</i> , 2017, 86, 1-4.	1.3	16
335	Deletion of the von Hippel-Lindau Gene in Hemangioblasts Causes Hemangioblastoma-like Lesions in Murine Retina. <i>Cancer Research</i> , 2018, 78, 1266-1274.	0.4	16
336	A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/ $\alpha^0$ rats. <i>Endocrine-Related Cancer</i> , 2020, 27, 337-354.	1.6	16
337	Regulation of Peripheral Catecholamine Responses to Acute Stress in Young Adult and Aged F-344 Rats. <i>Stress</i> , 1997, 2, 113-122.	0.8	15
338	Cardiac Uptake-1 Inhibition by High Circulating Norepinephrine Levels in Patients with Pheochromocytoma. <i>Hypertension</i> , 2004, 43, 1227-1232.	1.3	15
339	Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells. <i>Molecular Carcinogenesis</i> , 2008, 47, 245-251.	1.3	15
340	Unexplained Symptomatic Paroxysmal Hypertension in Pseudopheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2008, 1148, 469-478.	1.8	15
341	Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla. <i>Cell and Tissue Research</i> , 2010, 340, 607-612.	1.5	15
342	Comparison of clinical and imaging features in succinate dehydrogenase-positive versus sporadic paragangliomas. <i>Surgery</i> , 2011, 150, 1186-1193.	1.0	15

#	ARTICLE	IF	CITATIONS
343	Plasma-free deconjugated metanephrines for diagnosis of pheochromocytoma. <i>Clinical Endocrinology</i> , 2013, 79, 476-483.	1.2	15
344	Combination of 13-Cis Retinoic Acid and Lovastatin: Marked Antitumor Potential In Vivo in a Pheochromocytoma Allograft Model in Female Athymic Nude Mice. <i>Endocrinology</i> , 2014, 155, 2377-2390.	1.4	15
345	Preoperative Imaging Features are Associated with Surgical Complications Following Carotid Body Tumor Resection. <i>World Journal of Surgery</i> , 2015, 39, 2084-2089.	0.8	15
346	18F-DOPA: the versatile radiopharmaceutical. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1187-1189.	3.3	15
347	A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2V617F positive polycythemia vera: a case report. <i>BMC Cancer</i> , 2018, 18, 286.	1.1	15
348	Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery. <i>Annals of Surgery</i> , 2019, 269, 741-747.	2.1	15
349	Characteristic CT features of pheochromocytomas - probability model calculation tool based on a multicentric study. <i>Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia</i> , 2019, 163, 212-219.	0.2	15
350	Characteristics of Blood Pressure in Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 86-93.	1.8	14
351	Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. <i>Endocrine-Related Cancer</i> , 2007, 14, 463-471.	1.6	14
352	Neuropeptide Y expression in pheochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome. <i>Journal of Endocrinology</i> , 2007, 193, 225-233.	1.2	14
353	Cytocidal Activities of Topoisomerase 1 Inhibitors and 5-Azacytidine against Pheochromocytoma/Paraganglioma Cells in Primary Human Tumor Cultures and Mouse Cell Lines. <i>PLoS ONE</i> , 2014, 9, e87807.	1.1	14
354	Genetics, Diagnosis, and Management of Medullary Thyroid Carcinoma and Pheochromocytoma/Paraganglioma. <i>Endocrine Practice</i> , 2014, 20, 176-187.	1.1	14
355	Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. <i>PET Clinics</i> , 2015, 10, 477-486.	1.5	14
356	Nuclear Medicine in Cancer Theranostics: Beyond the Target. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1659-1660.	2.8	14
357	Are patients with hormonally functional pheochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study. <i>Clinical Endocrinology</i> , 2016, 85, 62-69.	1.2	14
358	A Previously Unrecognized Monocytic Component of Pheochromocytoma and Paraganglioma. <i>Endocrine Pathology</i> , 2019, 30, 90-95.	5.2	14
359	Why Take the Risk? We Only Live Once: The Dangers Associated with Neglecting a Pre-Operative Alpha Adrenoceptor Blockade in Pheochromocytoma Patients. <i>Endocrine Practice</i> , 2019, 25, 106-108.	1.1	14
360	Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker. <i>International Journal of Cancer</i> , 2020, 146, 2326-2335.	2.3	14

#	ARTICLE	IF	CITATIONS
361	Developmental vascular malformations in EPAS1 gain-of-function syndrome. JCI Insight, 2021, 6, .	2.3	14
362	Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. Journal of Nuclear Medicine, 2021, 62, 1192-1199.	2.8	14
363	Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma. Nuclear Medicine and Biology, 2012, 39, 215-226.	0.3	13
364	Diagnostic Imaging of Pheochromocytoma. , 2003, 31, 107-120.		12
365	Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty. Journal of Pediatric Endocrinology and Metabolism, 2014, 27, 837-44.	0.4	12
366	Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells. Endocrinology, 2015, 156, 4094-4104.	1.4	12
367	Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma. FASEB Journal, 2017, 31, 2226-2240.	0.2	12
368	Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using <sup>68</sup> Ga-DOTATATE, FDG, <sup>18</sup> F-FDOPA, and Tl-201) in 50 Patients. J Clin Endocrinol Metab, 2019, 101, 1-10.	1.2	12
369	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. Endocrine-Related Cancer, 2022, 29, 285-306.	1.6	12
370	Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. Endocrine-Related Cancer, 2022, 29, 213-224.	1.6	12
371	Triiodothyronine attenuates estradiol-induced increases in dopamine D-2 receptor number in rat anterior pituitary. Brain Research, 1996, 712, 148-152.	1.1	11
372	Hyperinsulinemia and Sympathoadrenal System Activity in the Rat. Annals of the New York Academy of Sciences, 1997, 827, 118-134.	1.8	11
373	Management of Malignant Pheochromocytoma. , 2002, 12, 291-299.		11
374	Anatomical and Functional Imaging of Tumors in Animal Models: Focus on Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 392-404.	1.8	11
375	CSF Catecholamine Profile in Subarachnoid Hemorrhage Patients with Neurogenic Cardiomyopathy. Neurocritical Care, 2011, 14, 401-406.	1.2	11
376	Metanephrines for Evaluating Palpitations and Flushing. JAMA - Journal of the American Medical Association, 2017, 318, 385.	3.8	11
377	Prospective evaluation of <sup>68</sup> Ga-DOTATATE PET/CT in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. Clinical Endocrinology, 2018, 89, 155-163.	1.2	11
378	A Clinical Roadmap to Investigate the Genetic Basis of Pediatric Pheochromocytoma: Which Genes Should Physicians Think About?. International Journal of Endocrinology, 2018, 2018, 1-14.	0.6	11

#	ARTICLE	IF	CITATIONS
379	Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity. <i>Seminars in Oncology</i> , 2019, 46, 385-392.	0.8	11
380	MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas. <i>Journal of Surgical Research</i> , 2019, 243, 1-7.	0.8	11
381	Nonmosaic somatic <i>HIF2A</i> mutations associated with late onset polycythemia—paraganglioma syndrome: Newly recognized subclass of polycythemia—paraganglioma syndrome. <i>Cancer</i> , 2019, 125, 1258-1266.	2.0	11
382	Induction of Immune Response against Metastatic Tumors via Vaccination of Mannan- $\beta$ M, TLR Ligands, and Anti-CD40 Antibody (MBTA). <i>Advanced Therapeutics</i> , 2020, 3, 2000044.	1.6	11
383	Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2020, 110, 154297.	1.5	11
384	Variants and Pitfalls of PET/CT in Neuroendocrine Tumors. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 519-528.	2.5	11
385	A New Concept of Unopposed $\beta$ -Adrenergic Overstimulation in a Patient with Pheochromocytoma. <i>Annals of Internal Medicine</i> , 2005, 142, 1026.	2.0	11
386	Local sympathetic function in human skeletal muscle and adipose tissue assessed by microdialysis. <i>Clinical Autonomic Research</i> , 2002, 12, 13-19.	1.4	10
387	Phospho-mTOR is not upregulated in metastatic SDHB paragangliomas. <i>European Journal of Clinical Investigation</i> , 2013, 43, 970-977.	1.7	10
388	Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas. <i>Annals of Surgery</i> , 2016, 263, 582-587.	2.1	10
389	In vivo detection of catecholamines by magnetic resonance spectroscopy: A potential specific biomarker for the diagnosis of pheochromocytoma. <i>Surgery</i> , 2016, 159, 1231-1233.	1.0	10
390	Mass spectrometric quantification of salivary metanephrines—A study in healthy subjects. <i>Clinical Biochemistry</i> , 2016, 49, 983-988.	0.8	10
391	Leptomeningeal dissemination of a low-grade lumbar paraganglioma: case report. <i>Journal of Neurosurgery: Spine</i> , 2017, 26, 501-506.	0.9	10
392	Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice. <i>Endocrinology</i> , 2017, 158, 3097-3108.	1.4	10
393	Blood collection in unstressed, conscious, and freely moving mice through implantation of catheters in the jugular vein: a new simplified protocol. <i>Physiological Reports</i> , 2018, 6, e13904.	0.7	10
394	RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. <i>Cancers</i> , 2018, 10, 518.	1.7	10
395	Cardiometabolic risk factors and health behaviors in family caregivers. <i>PLoS ONE</i> , 2017, 12, e0176408.	1.1	10
396	Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models. <i>Oncotarget</i> , 2016, 7, 40531-40545.	0.8	10

#	ARTICLE	IF	CITATIONS
397	Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells. <i>American Journal of Cancer Research</i> , 2015, 5, 1558-70.	1.4	10
398	Utility of Plasma Free Metanephrines in Diagnosis of Factitious Pheochromocytoma. <i>Endocrine Practice</i> , 2006, 12, 568-571.	1.1	9
399	Animal Models of Pheochromocytoma Including NIH Initial Experience. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 300-305.	1.8	9
400	High-Throughput Screening for the Identification of New Therapeutic Options for Metastatic Pheochromocytoma and Paraganglioma. <i>PLoS ONE</i> , 2014, 9, e90458.	1.1	9
401	Endocrine tumors associated with the vagus nerve. <i>Endocrine-Related Cancer</i> , 2016, 23, R371-R379.	1.6	9
402	Functional Imaging Experience in a Germline Fumarate Hydratase Mutation-Positive Patient With Pheochromocytoma and Paraganglioma. <i>AACE Clinical Case Reports</i> , 2016, 2, e176-e181.	0.4	9
403	Determination of the unmetabolised 18F-FDG fraction by using an extension of simplified kinetic analysis method: clinical evaluation in paragangliomas. <i>Medical and Biological Engineering and Computing</i> , 2016, 54, 103-111.	1.6	9
404	Pseudopheochromocytoma. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 751-764.	1.2	9
405	Ivabradine in Catecholamine-Induced Tachycardia in a Patient with Paraganglioma. <i>New England Journal of Medicine</i> , 2019, 380, 1284-1286.	13.9	9
406	Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 223-230.	0.6	9
407	Prognostic and predictive value of nuclear imaging in endocrine oncology. <i>Endocrine</i> , 2020, 67, 9-19.	1.1	9
408	Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide. <i>Nuclear Medicine and Molecular Imaging</i> , 2020, 54, 48-52.	0.6	9
409	C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 315-321.	3.1	9
410	Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. <i>Cancers</i> , 2021, 13, 3312.	1.7	9
411	A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy. <i>Endocrine-Related Cancer</i> , 2021, 28, 731-744.	1.6	9
412	Chiari Malformation Type 1 in EPAS1-Associated Syndrome. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2819.	1.8	8
413	Gs $\alpha$ deficiency in the dorsomedial hypothalamus leads to obesity, hyperphagia, and reduced thermogenesis associated with impaired leptin signaling. <i>Molecular Metabolism</i> , 2019, 25, 142-153.	3.0	8
414	Phaeochromocytoma "advances through science, collaboration and spreading the word. <i>Nature Reviews Endocrinology</i> , 2020, 16, 621-622.	4.3	8



#	ARTICLE	IF	CITATIONS
415	A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses. <i>Journal of Nuclear Medicine</i> , 2021, 62, 26S-33S.	2.8	8
416	Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review. <i>World Journal of Urology</i> , 2022, 40, 385-390.	1.2	8
417	How do levels of (endogenous) glucocorticoids, interleukin-10 and interleukin-12 relate to multiple sclerosis relapse before, during and after pregnancy?. <i>Clinical Endocrinology</i> , 1999, 50, 818-819.	1.2	7
418	Combined corticotropin-releasing hormone and glucocorticoid deficiency does not enhance counterregulatory responses after recurrent hypoglycemia in mice. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1259-1265.	1.5	7
419	Association between sympathetic response, neurogenic cardiomyopathy, and venous thromboembolization in patients with primary subarachnoid hemorrhage. <i>Acta Neurochirurgica</i> , 2013, 155, 1501-1510.	0.9	7
420	Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations. <i>Endocrine</i> , 2018, 61, 216-223.	1.1	7
421	Genetic Determinants of Pheochromocytoma and Paraganglioma Imaging Phenotypes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 643-645.	2.8	7
422	Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3455.	1.8	7
423	Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy. <i>Cancers</i> , 2021, 13, 3942.	1.7	7
424	Pheochromocytoma. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, E1-E1.	3.3	7
425	Epidural anesthesia and hypotension in pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2020, 27, 519-527.	1.6	7
426	AN AGGRESSIVE TEMPORAL BONE SDHC PARAGANGLIOMA ASSOCIATED WITH INCREASED HIF-2 $\pm$ SIGNALING. <i>Endocrine Practice</i> , 2016, 22, 190-195.	1.1	6
427	Radiopharmaceuticals in paraganglioma imaging: too many members on board?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 391-393.	3.3	6
428	Current experts'™ views on precision nuclear medicine imaging of phaeochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2223-2224.	3.3	6
429	Gallbladder Paraganglioma Associated with SDHD Mutation: a Potential Pitfall on 18F-FDOPA PET Imaging. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 144-147.	0.6	6
430	Phaeochromocytoma and pregnancy: looking towards better outcomes, less fear, and valuable recommendations. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 2-3.	5.5	6
431	Functional significance of germline EPAS1 variants. <i>Endocrine-Related Cancer</i> , 2021, 28, 97-109.	1.6	6
432	Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6

#	ARTICLE	IF	CITATIONS
433	Adenoviral Gene Transfer in Bovine Adrenomedullary and Murine Pheochromocytoma Cells: Potential Clinical and Therapeutic Relevance. <i>Endocrinology</i> , 2007, 148, 3900-3907.	1.4	5
434	Mitochondrial Localization of Human Recombinant Adenovirus: From Evolution to Gene Therapy. <i>NeuroImmunoModulation</i> , 2007, 14, 221-223.	0.9	5
435	Development and validation of a comprehensive mutation and deletion detection assay for SDHB, SDHC, and SDHD. <i>Clinical Biochemistry</i> , 2010, 43, 700-704.	0.8	5
436	Diagnostic Investigation of Lesions Associated with Succinate Dehydrogenase Defects. <i>Hormone and Metabolic Research</i> , 2019, 51, 414-418.	0.7	5
437	Neuraxial dysraphism in EPAS1-associated syndrome due to improper mesenchymal transition. <i>Neurology: Genetics</i> , 2020, 6, e414.	0.9	5
438	Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3303-3312.	2.0	5
439	Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma. <i>Frontiers in Endocrinology</i> , 2021, 12, 731096.	1.5	5
440	The role of dopamine in methylene blue-mediated inhibition of estradiol benzoate-induced anterior pituitary hyperplasia in rats. <i>Neuroscience Letters</i> , 2001, 304, 194-198.	1.0	4
441	Double stable isotope ultra performance liquid chromatographic-tandem mass spectrometric quantification of tissue content and activity of phenylethanolamine N-methyltransferase, the crucial enzyme responsible for synthesis of epinephrine. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 1713-1719.	1.9	4
442	<sup>18</sup> F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1849-1854.	2.8	4
443	Implications of SDHB genetic testing in patients with sporadic pheochromocytoma. <i>Langenbeck's Archives of Surgery</i> , 2017, 402, 787-798.	0.8	4
444	Paraganglioma of the organ of Zuckerkandl associated with a somatic HIF2 $\alpha$ mutation: A case report. <i>Oncology Letters</i> , 2017, 13, 1083-1086.	0.8	4
445	Mathematical modeling of disease dynamics in SDHB- and SDHD-related paraganglioma: Further step in understanding hereditary tumor differences and future therapeutic strategies. <i>PLoS ONE</i> , 2018, 13, e0201303.	1.1	4
446	Tumor multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: A <sup>18</sup> F- $\beta$ -DOPA PET/CT study. <i>Head and Neck</i> , 2019, 41, 1565-1571.	0.9	4
447	Surgical Resection of Pheochromocytomas and Paragangliomas is Associated with Lower Cholesterol Levels. <i>World Journal of Surgery</i> , 2020, 44, 552-560.	0.8	4
448	Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome. <i>JAMA Ophthalmology</i> , 2020, 138, 148.	1.4	4
449	Clinical manifestations of Pacak-Zhuang syndrome in a male pediatric patient. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28096.	0.8	4
450	Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma. <i>Frontiers in Endocrinology</i> , 2020, 11, 587065.	1.5	4

#	ARTICLE	IF	CITATIONS
451	Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity. <i>Molecules</i> , 2021, 26, 6567.	1.7	4
452	18F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020, 2020, .	0.2	4
453	A novel germline gain-of-function HIF2A mutation in hepatocellular carcinoma with polycythemia. <i>Aging</i> , 2020, 12, 5781-5791.	1.4	4
454	Sympathoneural and skeletal muscle contributions to plasma DOPA responses in pithed rats. <i>Journal of the Autonomic Nervous System</i> , 1991, 35, 169-174.	1.9	3
455	Genomic Medicine. <i>Annals of the New York Academy of Sciences</i> , 2002, 970, 177-192.	1.8	3
456	Pheochromocytoma: Unmasking the Chameleon. , 2013, , 123-148.		3
457	Precision Medicine in Adrenal Disorders: the Next Generation. <i>Endocrine Practice</i> , 2017, 23, 672-679.	1.1	3
458	Relevant Discordance Between 68Ga-DOTATATE and 68Ga-DOTANOC in SDHB-Related Metastatic Paraganglioma. <i>Clinical Nuclear Medicine</i> , 2017, 42, 211-213.	0.7	3
459	Reply: 68Ga-DOTATATE PET/CT Versus MRI: Why the Comparison of 68Ga-DOTATATE PET/CT to an Appropriate MRI Protocol Is Essential. <i>Journal of Nuclear Medicine</i> , 2017, 58, 185-185.	2.8	3
460	Successful induction therapy with sequential CVD followed by high-dose lanreotide in for metastatic SDHB paraganglioma: Case report. <i>Journal of Clinical and Translational Endocrinology: Case Reports</i> , 2018, 7, 8-13.	0.4	3
461	Exploring the link between tumour metabolism and succinate dehydrogenase deficiency: A <sup>18</sup> F-FDOPA PET/CT study in head and neck paragangliomas. <i>Clinical Endocrinology</i> , 2019, 91, 879-884.	1.2	3
462	Imaging of Small Intestine Neuroendocrine Neoplasms: Is SSTR PET the Holy Grail?. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1347-1348.	2.8	3
463	Reactive Oxygen Species: A Promising Therapeutic Target for SDHx-Mutated Pheochromocytoma and Paraganglioma. <i>Cancers</i> , 2021, 13, 3769.	1.7	3
464	Quantitative biomarkers allow the diagnosis of head and neck paraganglioma on multiparametric MRI. <i>European Journal of Radiology</i> , 2021, 143, 109911.	1.2	3
465	Supportive management of patients with pheochromocytoma/paraganglioma undergoing noninvasive treatment. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2022, 29, 294-301.	1.2	3
466	Effects of hypercortisolemia or hyperinsulinemia on neurochemical indices of catecholamine release and synthesis in conscious rats. <i>Journal of the Autonomic Nervous System</i> , 1995, 54, 104-112.	1.9	2
467	Familial pheochromocytomas and paragangliomas associated with mutations of the succinate dehydrogenase genes. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 399-406.	1.2	2
468	Multidisciplinary management of locally advanced and widely metastatic paraganglioma in a patient with life-threatening compressive symptoms. <i>Head and Neck</i> , 2015, 37, E205-8.	0.9	2

#	ARTICLE	IF	CITATIONS
469	Pheochromocytoma and Paraganglioma Syndromes. , 2015, , 449-454.		2
470	Rapidly Growing Chest Wall Mass in a Case of Sporadic Metastatic Paraganglioma. Clinical Nuclear Medicine, 2016, 41, 399-400.	0.7	2
471	PET Imaging for Endocrine Malignancies: From Woe to Go. Journal of Nuclear Medicine, 2017, 58, 878-880.	2.8	2
472	Pheochromocytoma/Paraganglioma: Update on Diagnosis and Management. Contemporary Endocrinology, 2018, , 261-310.	0.3	2
473	Some Considerations in Treating Malignant Head and Neck Paragangliomas. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 209.	1.2	2
474	Diagnostic Accuracy of Salivary Metanephrines in Pheochromocytomas and Paragangliomas. Clinical Chemistry, 2021, 67, 1090-1097.	1.5	2
475	Pheochromocytoma Resection: The Rule of Surgical Divergence. AACE Clinical Case Reports, 2016, 2, e78-e79.	0.4	2
476	Functional Imaging of Neuroendocrine Tumors: Stacking the Odds in a Patient's Favor. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3953-e3954.	1.8	2
477	Uncommon Endocrine Tumors in Children and Adolescents. , 2006, , 775-797.		1
478	When is a phaeo not a phaeo? Depression in an adolescent leading to a phaeochromocytoma-like biochemical profile. Clinical Endocrinology, 2011, 75, 567-568.	1.2	1
479	Multitracer PET imaging of bone metastases from paraganglioma: peripheral halo of uptake on 18F-FLT PET mismatching with central uptake of 18F-FDOPA, 18F-fluorodopamine, and 18F-FDG. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1928-1929.	3.3	1
480	A Necessity, not a Second Thought: Pre-Operative Alpha-Adrenoceptor Blockade in Pheochromocytoma Patients. Endocrine Practice, 2019, 25, 200-201.	1.1	1
481	Molecular Imaging in the Era of Precision Medicine: Paraganglioma as a Template for Understanding Multiple Levels of Analysis. Journal of Nuclear Medicine, 2020, 61, 646-648.	2.8	1
482	A long noncoding RNA's microRNA expression signature predicts metastatic signature in pheochromocytomas and paragangliomas. Endocrine, 2021, , 1.	1.1	1
483	The Global Reading Room: Nuclear Medicine Imaging of Suspected Paraganglioma. American Journal of Roentgenology, 2021, 217, 1008-1009.	1.0	1
484	Pheochromocytoma Hypertensive Crisis. , 2014, , 139-147.		1
485	Response to Letter to the Editor by Dullaart <i>et al.</i> . Clinical Endocrinology, 2010, 72, 569-570.	1.2	0
486	Commentary. Clinical Chemistry, 2013, 59, 1565-1565.	1.5	0

#	ARTICLE	IF	CITATIONS
487	Uncommon spreading of primary malignant paraganglioma in a patient with SDHB mutation. Case Reports in Internal Medicine, 2016, 4, 63.	0.0	0
488	The Author's Reply: inappropriate adrenoreceptor blockade prior to pheochromocytoma removal – a timely reappraisal™. Clinical Endocrinology, 2016, 85, 990-991.	1.2	0
489	Radionuclide Imaging of Head and Neck Paragangliomas. , 2017, , 269-294.		0
490	Radionuclide Imaging of Chromaffin Cell Tumors. , 2017, , 295-319.		0
491	Recent advances in the imaging of pheochromocytomas and paragangliomas. International Journal of Endocrine Oncology, 2017, 4, 137-144.	0.4	0
492	Management of Pheochromocytoma and Paraganglioma. , 2017, , 179-206.		0
493	Imaging Modalities for Pheochromocytoma and Paraganglioma. , 2017, , 125-138.		0
494	New Challenges in Nuclear Endocrinology. Journal of Nuclear Medicine, 2018, 59, 573-574.	2.8	0
495	SDHD Gene Mutations: Looking Beyond Head and Neck Tumors. AACE Clinical Case Reports, 2018, 4, 186-190.	0.4	0
496	More on Ivabradine in Tachycardia with Paraganglioma. New England Journal of Medicine, 2019, 380, 2590-2590.	13.9	0
497	Pheochromocytoma Hypertensive Crisis. Contemporary Endocrinology, 2021, , 137-145.	0.3	0
498	Somatic Mosaicism of EPAS1 Mutations in Pacak-Zhuang Syndrome. Endocrine Practice, 2022, , .	1.1	0